AX-2026-041314
ARA-290 · 4 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2511-S3009
- Report ID
- AX-2026-041314
- Compound
- ARA-290
- Compound class
- Tissue-repair and immunomodulatory peptides
- Supplier
- WWB — Wuhan Wansheng Biotechnology Co., Ltd.
- Batch / lot
- WWB-2511-S3009
- Declared label claim
- 4mg
- Laboratory
- PeptideMeter
- Assay date
- 17 Feb 2026
- Submitted
- 15 Mar 2026
- Quarter
- 2026-Q1
- Submitter
- br.osei
- Sample provenance
- Laboratory-retained
Results
Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 28 min gradient, 214 nm | 99.45 | % area | ≥ 98.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.55 | % area | ≤ 2.0 | PASS |
| Largest single impurity | RP-HPLC — deamidated (+1 Da) | 0.20 | % area | ≤ 1.00 | PASS |
| Identity | not ordered on this submission | not determined | — | required for VERIFIED status | NOT TESTED |
| Peptide content | not ordered on this submission | not determined | — | required to check label claim | NOT TESTED |
| Water content | Karl Fischer, coulometric, duplicate | 4.87 | % | ≤ 10.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.36 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.19 | % | — | NOT TESTED |
| Endotoxin | kinetic chromogenic LAL | 1.59 | EU/mg | ≤ 5.0 | PASS |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White cake, partially collapsed | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Slow dissolution, >5 min to clarity | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.09 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 28 min gradient | 8.28 | min | 8.19 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.28 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 86,246 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [D-Ser]-diastereomer | 0.97 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | ARA-290 — main peak | 8.28 | 4,833,578 | 99.45 | — |
| 2 | deamidated (+1 Da) | 8.07 | 9,721 | 0.20 | +0.984 |
| 3 | des-Gln truncate (−128 Da) | 8.00 | 8,263 | 0.17 | -128.059 |
| 4 | acetyl adduct (+42 Da) | 8.65 | 5,832 | 0.12 | +42.011 |
| 5 | [D-Ser]-diastereomer | 8.17 | 2,916 | 0.06 | 0.000 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 99.45 | divergence -0.03 pp vs batch median |
| Total impurities (% area) | 0.10 | 0.55 | |
| Largest single impurity (% area) | 0.07 | 0.20 | |
| Water (%) | 2.5 | 4.87 | |
| Counter-ion (%) | 6.5 | 4.36 | |
| Peptide content (%w/w) | 90.4 | not determined | |
| Endotoxin (EU/mg) | 0.96 | 1.59 | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Laboratory-retained
- Evidentiary weight
- Provenance documented, selection uncontrolled.
- Chain of custody
- Laboratory retained sample (−20 °C, 2 d since original receipt) → re-assay.
- Assay date
- 17 Feb 2026
- Submitted to the index
- 15 Mar 2026
- Laboratory
- PeptideMeter, Tallinn, Estonia
- Method basis
- 28 min gradient · high-resolution MS
- Verification status
- PURITY ONLY
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Related records
Same batch — lot WWB-2511-S3009 n=10
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041313 | WWB-2511-S3009 | Nordanalyt | 2026-Q1 | 99.93 | 4.81 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041315 | WWB-2511-S3009 | PeptideMeter | 2026-Q1 | 99.93 | 4.83 | 98.4 | Supplier-supplied | 0 | PASS |
| AX-2026-041316 | WWB-2511-S3009 | Janoshik | 2026-Q1 | 99.79 | 5.17 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041317 | WWB-2511-S3009 | Janoshik | 2026-Q1 | 99.93 | 4.60 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041318 | WWB-2511-S3009 | Medutest | 2026-Q1 | 99.93 | 4.44 | 107.4 | Supplier-supplied | 0 | PASS |
| AX-2026-041319 | WWB-2511-S3009 | PeptideMeter | 2026-Q1 | 99.88 | 5.10 | 89.2 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041320 | WWB-2511-S3009 | Janoshik | 2026-Q1 | 99.42 | 5.13 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041321 | WWB-2511-S3009 | Janoshik | 2026-Q1 | 99.93 | 4.64 | 93.0 | Supplier-supplied | 0 | PASS |
| AX-2026-041322 | WWB-2511-S3009 | Janoshik | 2026-Q1 | 99.93 | 5.26 | — | Supplier-supplied | 0 | PASS |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041852 | JEEP | JEEP-2601-K3139 | Janoshik | 2026-Q2 | 99.03 | 4.60 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-043211 | SGN | SGN-2605-X9661 | PeptideMeter | 2026-Q2 | 97.96 | 7.11 | 101.7 | Supplier-supplied | 1 | FAIL |
| AX-2026-041857 | JEEP | JEEP-2601-K3139 | Kestrel | 2026-Q2 | 99.09 | 4.21 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043212 | SGN | SGN-2605-X9661 | PeptideMeter | 2026-Q2 | 98.58 | 7.00 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041853 | JEEP | JEEP-2601-K3139 | PeptideMeter | 2026-Q2 | 98.50 | 4.51 | 94.7 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041856 | JEEP | JEEP-2601-K3139 | Janoshik | 2026-Q2 | 99.63 | 4.29 | 92.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041851 | JEEP | JEEP-2601-K3139 | Janoshik | 2026-Q2 | 99.00 | 4.51 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041858 | JEEP | JEEP-2601-K3139 | VendorInvestigate | 2026-Q2 | 98.82 | 4.14 | — | Buyer-sourced | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041275 | Liraglutide | WWB-2607-X2189 | Nordanalyt | 2026-Q3 | 99.61 | 5.03 | 97.3 | Supplier-supplied | 0 | PASS |
| AX-2026-041387 | BPC-157 | WWB-2606-H3906 | Janoshik | 2026-Q3 | 98.95 | 4.64 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-041334 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 98.83 | 5.04 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041337 | Semaglutide | WWB-2606-N3192 | Nordanalyt | 2026-Q3 | 98.96 | 4.81 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041385 | BPC-157 | WWB-2606-H3906 | Medutest | 2026-Q3 | 99.31 | 4.31 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041390 | BPC-157 | WWB-2606-H3906 | Medutest | 2026-Q3 | 99.47 | 4.84 | 99.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041386 | BPC-157 | WWB-2606-H3906 | VendorInvestigate | 2026-Q3 | 99.32 | 4.88 | 99.2 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-041335 | Semaglutide | WWB-2606-N3192 | Janoshik | 2026-Q3 | 99.55 | 4.55 | 100.5 | Supplier-supplied | 1 | MARGINAL |